Behzad Khosrowshahi became President and CEO in 2002 following the going-private acquisition of Drug Royalty Corporation. Behzad subsequently re-organized the investment manager as DRI Capital and has grown assets under management more than twenty fold.
Behzad chairs the DRI Capital Investment Committee. He is responsible for DRI Capital's direction and strategy, and has broad oversight over asset identification, sourcing, due diligence efforts, transaction execution, financings and investor relations. Behzad is closely involved with the existing DRI Capital funds' global base of institutional investors including public and private pension plans, foundations, university endowments, funds of funds, family offices, high net worth individuals and sovereign wealth funds.
Previously, Behzad held senior positions at Future Shop Ltd., where he rose to head its merchandising, marketing, e-commerce, and supply chain functions. When Future Shop Ltd. was sold to Best Buy Inc. for $580 million in 2001, the company was Canada's largest consumer electronics retailer, having grown from $1.3 billion in annual revenue and 2,500 employees to over $2 billion in annual revenue and more than 10,000 employees.
Behzad began his career at Deloitte LLP and is a Chartered Accountant. He received a B.A. in History from Reed College.
Andrea’s responsibilities include research and investment analysis, deal execution, portfolio analytics, financing and investor relations. She is a member of the Investment Committee and the chair of the Valuation Committee.
Since joining DRI Capital in 2003, Andrea has led the evaluation of more than 200 pharmaceutical products in 16 of the global top 20 therapeutic classes, developing substantial expertise in the scientific, clinical, regulatory and commercial aspects of the pharmaceutical industries operating in the United States, Europe and Japan. Andrea has conducted diligence that led to the acquisition of more than 40 different royalty assets. Since 2010, Andrea has played a leading role in the debt issuances for DRI’s managed funds. She has also played an active role in raising more than $2.3 billion in equity commitments for DRI’s managed funds.
Prior to joining DRI Capital, Andrea worked at Sanofi Pasteur, the vaccines division of Sanofi, where she contributed to global licensing applications and regulatory filings. In addition, she was instrumental in the launch of a new vaccine manufacturing facility. Andrea began her career at Allelix Biopharmaceuticals Inc. (now NPS Pharmaceuticals Inc.) where she conducted clinical analysis which contributed to the development of purification processes for two biologic products.
Andrea received a B.Sc. in Biochemistry with a specialization in Biotechnology from the University of Waterloo and an MBA from Queen's University. She is a member of the Women Business Leaders of the US Healthcare Industry Foundation.
Ali joined DRI Capital in 2002 and is a member of the firm's Investment Committee and Valuation Committee. Ali is responsible for leading the firm's new business and fund initiatives, and serves as the President and CEO of Ballast Healthcare Partners Inc., the public equity investment division of DRI Capital.
During his time at DRI Capital, Ali has held significant roles in investor relations, asset identification and research, financial modeling and deal structuring. Through such roles Ali has developed a detailed view of all elements of the royalty acquisition process and a broad understanding of the global biopharmaceutical industry.
Prior to joining DRI Capital, Ali served as Business Development Manager at Inwest Investments Ltd. (now Persis Holdings) where he evaluated over 70 venture capital investments. Ali began his career at the Claremont Technology Group as a consultant specializing in the design and implementation of enterprise resource planning and supply chain management systems. He later co-founded a spin-off company from the Massachusetts Institute of Technology which developed and commercialized technology used in the production of spherical metal powders.
Ali holds a B.A. in Physics from Reed College, a B.Sc. in Engineering and Applied Science from the California Institute of Technology, a M.Sc. in Mechanical Engineering from the Massachusetts Institute of Technology and an MBA from the Richard Ivey School of Business, University of Western Ontario. Ali has appeared as a market commentator on the Business News Network in Toronto.
Chris is responsible for overseeing DRI Capital’s finance, human resources and information technology functions.
Prior to joining DRI Capital in 2015 as Chief Financial Officer, Chris spent over 10 years at the Ontario Municipal Employees Retirement System (OMERS), an Ontario based pension plan with about $70 billion in assets. During his time at OMERS, Chris held progressively more senior Finance and Operations roles, including Vice President, Finance, Operations and Business Development with OMERS Investment Management, which raised domestic capital for OMERS; Vice President, Finance for OMERS Strategic Investments, which managed a portfolio of private markets assets and raised international capital for OMERS; and Director, Corporate Financial Reporting for OMERS Corporate office. Prior to OMERS, Chris spent seven years at TD Bank where he held senior Finance roles in TD Bank’s Subsidiaries and Affiliates Department and Chief Accountant’s Department. Chris began his career at KPMG LLP where he progressed to the position of Audit Manager.
Chris is a Chartered Professional Accountant (CA, CPA) and a Certified Valuation Analyst (CVA). Chris holds an MBA from the Rotman School of Management, University of Toronto and a B.Comm. from the University of Toronto.
Craig leads DRI's business development, legal and strategic planning functions, focusing on the sourcing, evaluation, acquisition and financing of healthcare royalties. He is a member of the firm’s Investment Committee.
Prior to joining DRI Capital in 2010 as Managing Director and General Counsel, Craig spent nearly eight years at Amgen. During his time at Amgen in the US and Europe, Craig held roles of progressive responsibility, including Executive Director and Associate General Counsel, with legal responsibility for the US Nephrology Business Unit and Amgen Canada, where he served on the executive committee for both business units; Senior Counsel to Amgen Europe and Amgen International based in Switzerland, where he worked in health systems across more than 35 country markets including those within Europe, Russia, Latin America, the Middle East and Gulf States; Counsel to Amgen USA and an intern in Amgen product licensing.
Craig began his legal career as a transactional lawyer with Morgan Lewis LLP in the United States, where he worked on a wide variety of M&A, venture capital, lending and high yield debt transactions, and with McCarthy Tetrault LLP in Canada. He is licensed to practice law in the State of California and the Province of Ontario.
Craig received an MBA from Harvard Business School, a law degree from McGill University, and a B.A. from the University of Western Ontario. He serves on the boards of Medcan Health Management Inc., the largest preventative healthcare clinic business in North America, and the American Kidney Fund.
Adam joined DRI Capital in 2013 as Vice President. He is responsible for transaction origination and business development activities among life sciences companies located worldwide.
For more than a decade prior to joining DRI, Adam provided financing advice to DRI and its managed royalty funds, most recently as Managing Director – Leveraged Finance and Sponsor Coverage at Macquarie Capital. In this role, Adam’s responsibilities included deal origination, execution of leverage finance transactions and strategically deploying the firm’s balance sheet. Adam was previously a Principal in Investment Banking at Bank of America Securities LLC in both New York and Toronto, an Associate in Investment Banking with Rothschild, and an M&A Analyst with CIBC World Markets. In these roles, Adam developed wide ranging expertise in deal sourcing, structuring, valuation, diligence and execution on a variety of acquisition, lending, high yield debt, restructuring and other capital markets assignments.
Adam holds a Bachelor of Commerce with a concentration in Finance and International Business from McGill University. He is also a CFA charterholder.
Gary became DRI's General Counsel and Chief Compliance Officer in August, 2013. He previously served as Deputy General Counsel and Chief Compliance Officer, Senior Counsel and Counsel. He joined DRI Capital in 2007 and is a member of the firm's Risk Management Committee. Gary is a leader in DRI's international patent, licensing, and regulatory due diligence, the negotiation and documentation of royalty acquisitions, as well as financings and governance matters. As Chief Compliance Officer, Gary administers DRI Capital's “No Shortcuts” compliance program, including overseeing the company's compliance-related policies and procedures.
Prior to joining DRI Capital, Gary was an Associate at New York-based law firms Dewey Ballantine, practicing in London, and Simpson Thacher & Bartlett LLP, practicing in New York, where he worked on a variety of transactions, including initial public offerings, M&A deals, and private equity fund formation and administration. He began his legal career at the Toronto-based law firm Osler, Hoskin & Harcourt LLP.
Gary holds a JD with Honours and a B.Sc. in Human Biology, both from the University of Toronto. Gary is licensed to practice law in the State of New York and the Province of Ontario.